Eli Lilly and Company (LLY)vsMaxCyte Inc (MXCT)
LLY
Eli Lilly and Company
$948.45
-2.72%
HEALTHCARE · Cap: $869.41B
MXCT
MaxCyte Inc
$0.84
-3.24%
HEALTHCARE · Cap: $90.34M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 218664% more annual revenue ($72.25B vs $33.03M). LLY leads profitability with a 35.0% profit margin vs -135.1%. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
MXCT
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+44.7%
Fair Value
$1.32
Current Price
$0.84
$0.48 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 108 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 27.2x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -23.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : MXCT
The strongest argument for MXCT centers on Price/Book, Debt/Equity.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : MXCT
The primary concerns for MXCT are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
LLY profiles as a growth stock while MXCT is a turnaround play — different risk/reward profiles.
MXCT carries more volatility with a beta of 1.57 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 30/100), backed by strong 35.0% margins and 55.5% revenue growth. MXCT offers better value entry with a 44.7% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →MaxCyte Inc
HEALTHCARE · MEDICAL DEVICES · USA
MaxCyte Inc. (MXCT) is a pioneering company in the field of cell-engineering, distinguished by its innovative Flow Electroporation® technology, which facilitates the efficient and scalable introduction of nucleic acids and proteins into various cell types. Serving a diverse clientele that includes leading biopharmaceutical companies and prominent research institutions, MaxCyte is strategically positioned in the burgeoning cell and gene therapy market. The company's cutting-edge platforms are integral to the development of novel cell-based therapies and vaccines, allowing it to seize substantial growth opportunities within the healthcare landscape. Committed to advancing transformative medical solutions, MaxCyte is set to meet the increasing global demand for innovative therapeutic approaches.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?